Advanced Pipeline
Click on programs to see 2014 highlights.
Therapy | Phase 1 | Phase 2 | Phase 3 | Marketed | |
---|---|---|---|---|---|
AMPYRA®(dalfampridine)
AMPYRA®(dalfampridine)
|
Walking in MS
|
|
|
|
|
ZANAFLEX® (tizanidine HCI)
ZANAFLEX® (tizanidine HCI) |
Spasticity
|
|
|
|
|
QUTENZA® (capsaicin)
QUTENZA® (capsaicin) |
Post-Shingles
Nerve Pain |
|
|
|
|
DALFAMPRIDINE
DALFAMPRIDINE
|
Chronic Post-Stroke
Walking Deficits |
|
|
|
|
CVT-301
CVT-301
|
Parkinson's Disease
|
|
|
|
|
PLUMIAZ™
PLUMIAZ™ |
Seizure Clusters
|
|
|
|
|
CIMAGLERMIN ALFA
CIMAGLERMIN ALFA
|
Heart Failure
|
|
|
|
|
rHlgM22
rHlgM22
|
MS
|
|
|
|
|
CVT-427
CVT-427Preparing for first Phase 1 clinical trial |
Migraine
Migraine
|
|
|
|
|